Drug: BI 836858 (Boehringer Ingelheim)
Status: Orphan drug designation for the treatment of myelodysplastic syndrome (MDS)
Significant Data:
- A monoclonal antibody that targets the CD33 protein
- Engineered for improved antibody-dependent cell-mediated cytotoxicity (ADCC)
- Preclinical studies with the compound have shown promising ADCC against malignant cells
- Phase I/II, multicenter, open-label, dose escalation, randomized trial (NCT02240706) evaluating BI 836858 in patients with MDS is